News | August 13, 2021
Wockhardt to manufacture and supply Sputnik V
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Demand normalisation post the second wave contributed to the steady growth
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
Anti-malaria API facility will be operational in 15-18 months
Income declines marginally
It plays a pivotal role in monitoring pharmaceutical pricing
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
